ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ABOS / earnings
DYAI (31) SCLX (40) PLUR (34) JSPR (36) ⌘ Pro Terminal →

Acumen Pharmaceuticals Inc. (ABOS) Next Earnings Date & Expected ±12.5% Move

$0.24 +14.09% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.25

Acumen Pharmaceuticals Inc. (ABOS) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $15.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ABOS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ABOS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Acumen Pharmaceuticals Inc. (NASDAQ: ABOS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.24 (+14.09% 1D, market cap $15.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ABOS ranks #698 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ABOS compare to DYAI and SCLX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ABOS carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DYAI (Dyadic International Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M) and SCLX (Scilex Holding Company) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $15.7M). Among the 5-stock peer group, ABOS leads on earnings multiple (N/A) while ABOS leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ABOS?
▼

Per ABOS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001576885), Acumen Pharmaceuticals Inc. generated $346.7M in revenue (+8.6% YoY), -$121.3M in net income, and -$115.5M in free cash flow against $122.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.25 (+2.35%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (6)Whales (4)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-12.5% Base Target
$4 Bull$0 Base$0 Bear
📬 FREE ABOS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABOS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY ABOS SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 20.3 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$2.02-12.4% Next Q
Q2 (-2Q)
38
Grade E$1.77+28.2% Next Q
Q3 (-1Q)
36
Grade E$2.27-89.4% Next Q
Current
33
Grade E$0.24-8.9% Hist 90D α
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ABOS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ABOS currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.35) and Max Pain ($0.25) forces dealer call-delta covering toward $3.78.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABOS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ABOS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.03 Expected Swing
$1.00 (-12.5%)Spot $0.24$0.27 (+12.5%)
MODEL EARNINGS SETUP GAUGE

ABOS Quantitative Pre-Earnings Setup: 33/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (33/100)Model Risk Weight (67/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$346.7M-$121.3M-$115.5M52%
FY 20242024-12-31$319.2M-$102.3M-$86.2M52%
FY 20232023-12-31$171.2M-$52.4M-$43.1M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABOS)

  • ✓Walkthrough of ABOS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ABOS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -90.32%▼ SUPPORT BREAKDOWN
2026-11-03O $2.29H $2.29L $0.21C $0.24VOL 68.11M
RES: $3.77SUP: $1.52SMA50: $2.35SMA200: $2.49
$3.56$2.65$1.74$0.84$-0.07RES $3.77SUP $1.52$0.242026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABOS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ABOS Butterfly Map → + Track ABOS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +8.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ABOS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABOS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ABOS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABOS)

Health Care Rank #698 of 1015 ⚔️ DYAI vs ABOS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABOS vs. DYAI, SCLX, PLUR, JSPR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Acumen Pharmaceuticals Inc. (ABOS) ranks #698 by composite RQD confidence (33/100, grade E) and #854 by equity capitalization ($15.2M). Within this direct 5-issuer industry benchmark cohort, ABOS leads on earnings valuation at N/A trailing P/E, while ABOS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SCLX currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with ABOS at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ABOS ACTIVE
Acumen Pharmaceuticals Inc.
E 33/100 — — -35.0% +14.09% $15.2M Benchmark Subject
DYAI
Dyadic International Inc.
E 31/100 — 24.9% -35.0% -1.10% $15.2M /dyai-vs-abos →
SCLX
Scilex Holding Company
D- 40/100 — 96.0% -35.0% +1.08% $15.7M /sclx-vs-abos →
PLUR
Pluri Inc.
E 34/100 — 49.0% -35.0% -3.23% $16.7M /plur-vs-abos →
JSPR
Jasper Therapeutics Inc.
D- 36/100 — — -35.0% -2.35% $17.3M /jspr-vs-abos →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001576885 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Acumen Pharmaceuticals Inc. (ABOS) reported GAAP revenue of $346.7M (+8.6% vs. FY2024 revenue of $319.2M , and +102.5% cumulative change since FY2023) , GAAP net income of -$121.3M, operating cash flow of -$115.5M, and free cash flow of -$115.5M (-34.0% YoY). On the balance sheet, ABOS closed FY2025 with $122.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $346.7M -$121.3M -$115.5M -$115.5M $122.8M —
FY2024 (FY) 2024-12-31 $319.2M -$102.3M -$86.2M -$86.2M $239.0M —
FY2023 (FY) 2023-12-31 $171.2M -$52.4M -$43.1M -$43.1M — —

3. ABOS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABOS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Acumen Pharmaceuticals Inc. (NASDAQ: ABOS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.24 (+14.09% 1D, market cap $15.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ABOS ranks #698 in composite RQD confidence.

How does ABOS compare to DYAI and SCLX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ABOS carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DYAI (Dyadic International Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M) and SCLX (Scilex Holding Company) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $15.7M). Among the 5-stock peer group, ABOS leads on earnings multiple (N/A) while ABOS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ABOS?

Per ABOS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001576885), Acumen Pharmaceuticals Inc. generated $346.7M in revenue (+8.6% YoY), -$121.3M in net income, and -$115.5M in free cash flow against $122.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ABOS trading relative to its 50-day, 200-day, and 52-week technical levels?

ABOS last traded at $0.24 (+14.09% on volume of 33,721,585 shares), positioning the stock -89.79% below its 50-day simple moving average ($2.35) and -90.36% below its 200-day simple moving average ($2.49). Across its 52-week range of $0.21 to $3.60, ABOS sits at the 0.9% percentile with a 14-day RSI of 20.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.27).

Direct Sub-Reports: ABOS RQD Cockpit ABOS 12M Forecast ABOS Earnings & Move ABOS Dividends & DRIP ABOS Insiders & 13F ABOS Whale Options ABOS Profit Sankey ABOS News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

ABOS — Acumen Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Acumen Pharmaceuticals Inc. (ABOS) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.24 (+14.09% 1D, market capitalization $15.2M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Acumen Pharmaceuticals Inc. (ABOS) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Reported revenue is — in each listed period, .

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Acumen Pharmaceuticals Inc. (ABOS) reported $346.7M in annual revenue (up from $319.2M in FY2024, +8.6% YoY) and -$121.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($171.2M revenue, -$52.4M net income) through FY2025, ABOS scaled operating cash flow to -$115.5M and free cash flow to -$115.5M, backed by $122.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 4/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $0.21 – $3.60 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream dependencies, downstream customers, or sector correlation mapping.

  • Key Question #1: Can ABOS sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $346.7M and free cash flow of -$115.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ABOS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ABOS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Acumen Pharmaceuticals Inc. (ABOS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ABOS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ABOS Bull vs. Bear Conversation Board — What's Your Call at $0.24?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABOS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ABOS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $0.25 (+19.0%)
📌 Pinned Debate

Cash rose from $35.6M to $54.0M in the latest reported year, despite negative free cash flow.

Long ABOS at $0.21 targeting $0.25. Cash rose from $35.6M to $54.0M in the latest reported year, despite negative free cash flow.. Institutional whale score is 4/20 and the risk/reward vs. the $0.21 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@MeanReversion_88 Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $0.18 (-14.3%)
Spot @ $0.21

Free cash flow was -$115.5M in FY 2025 against a 0% FCF yield, and the stock fell -90.83%.

I respect the product at Acumen Pharmaceuticals Inc., but the stock at $0.21 is a different story. Free cash flow was -$115.5M in FY 2025 against a 0% FCF yield, and the stock fell -90.83%.. FCF yield is 0.0% and RQD sits at 33/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%